IL18 and chronic kidney disease: Furthermore, a larger clinical study can determine the performance of TMAP in assessing CKD progression, inflammation and tubular injury including c-reactive protein, kidney injury molecule-1, IL-18, monocyte chemotactic protein-1 and YKL-4027 injury.